3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Recurrence
4
Immunoglobulin Light-chain Amyloidosis
3
Burkitt Lymphoma
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmacytoma
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Intraocular Lymphoma
1
Hypersensitivity
1
Hematologic Neoplasms
1
Interventions
Docetaxel
43
enzalutamide
31
Prednisone
25
Abiraterone Acetate
24
Magnetic Resonance Spectroscopy
18
abiraterone
15
pembrolizumab
14
bicalutamide
14
Radiotherapy
14
Cyclophosphamide
13
darolutamide
12
Leuprolide
12
Goserelin
12
apalutamide
10
Ipilimumab
10
olaparib
9
Specimen Handling
9
Radiosurgery
9
Radiation
9
Injections
9
Biopsy
9
Pluvicto
8
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Carboplatin
7
sargramostim
6
fludarabine
6
cabazitaxel
6
Sirolimus
6
Nivolumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms
×
dexamethasone acetate
×
Clear all
NCT06136598
2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1
Completed
14 enrolled